Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
November 07, 2024 16:01 ET
|
Skye Bioscience, Inc.
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways...
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model
November 04, 2024 07:00 ET
|
Skye Bioscience, Inc.
Peripherally-restricted nimacimab achieves significant dose-dependent weight loss, fat mass reduction, lean mass preservation, and glycemic control in diet-induced obesity model Preliminary data...
Skye Bioscience to Announce Third Quarter 2024 Results
November 01, 2024 07:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
October 29, 2024 07:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
October 21, 2024 07:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
September 23, 2024 07:00 ET
|
Skye Bioscience, Inc.
16-week top-line weight loss data validates mechanism of action targeting peripheral CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule...
Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer
September 03, 2024 07:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
August 26, 2024 07:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 23, 2024 18:45 ET
|
Skye Bioscience, Inc.
SAN DIEGO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
August 22, 2024 07:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...